GenePlanet, the Swiss-backed biotech company present in more than 30 countries worldwide, is in Nigeria this week presenting its innovative solutions in the field of genetic screening tests. The company has chosen Medic West Africa due to its importance as the premier B2B healthcare platform in the West African region. “Medic West Africa provides us with an opportunity to build a rich network with more than 4,200 of healthcare industry peers. It’s a great event to discuss the positive impacts of genetic testing with West African’s Ministries, authorities, healthcare providers and distributors”, says Marko Bitenc, GenePlanet’s CEO.
GenePlanet’s main product in the field of genetic screening tests is NIPT, a non-invasive prenatal test based on cell-free foetal DNA for detection of chromosomal aneuploidies. Using a new generation of sequencing technology, the test can identify the risk of certain genetic defects that may affect a child's health with sensitivity and specificity higher than 99%. The main syndromes screened by GenePlanet NIPT are Down (T21) – a global incidence of 1 in 700 children, Edwards (T18) – 1 in 5,000 and Patau (T13) – 1 in 8,000. In addition, it also examines more than 60 other chromosomal aberrations, which makes it the most comprehensive test in the market.
GenePlanet NIPT a safe prenatal test (no risk of miscarriage): it is performed using only a blood sample from the mother. “This is only possible because, during the pregnancy, the DNA originating from the placenta crosses into the mother’s bloodstream. From the blood sample, cell-free foetal DNA is analysed in order to examine the baby’s health and to check if there are any abnormalities”, says Marko Bitenc, GenePlanet’s CEO.
GenePlanet was one of the first companies to offer a non-invasive prenatal test in Europe being today one of the leaders in this field.
Besides GenePlanet’s NIPT, the company offers two other genetic tests aimed at future parents and their children. Carrier Screen is a complete and accurate genetic test for more than 600 genetic diseases. Newborn Screen ensures that babies are screened for 87 inherited disorders that can cause serious problems, some of them very severe or even life-threatening.
Newborn Screen ensures that babies are screened for certain serious conditions at birth, allowing doctors to start the treatment before any harmful effects develop. It screens for 87 inherited disorders that can cause serious problems, some of them very severe or even life-threatening. When diagnosed at an early stage, many of these diseases are treatable. In addition to disorders, with Newborn Screen the parents will also learn about their baby’s response to 32 different paediatric medications allowing doctors to safely adjust the dosage or recommend alternative medications for specific diseases.
GenePlanet offers the most comprehensive genetic test for hereditary cancer risk assessment. Cancer Screen is a non-invasive saliva-based test that screens for mutations in genes BRCA2 among others) associated with 17 different cancers including hereditary breast and ovarian cancer, colorectal, melanoma, ovarian, pancreatic, stomach and uterine cancers.
GenePlanet is specialised in genetic testing and related advanced molecular techniques and recognised for offering personalised DNA analyses. In addition to the screening tests mentioned above, the company also offers preventive DNA tests in the areas of nutrition, sports and rejuvenation. By being R&D oriented, GenePlanet constantly strives for new discoveries that enable it to provide its clients with the latest and best products developed from its in-house research and development. The company was founded in 2008 in Slovenia by Marko Bitenc, a Silicon Valley Singularity University alumnum.